Abacus Parenteral Drugs Limited

abacusparenteral.com

Trading in pharmaceutical products is one of core industry in Uganda‘s economy. As the manufacturers of pharmaceutical products are very few to cater the market demand, majority of demand was met through importation. This business is growing at a rapid pace with the growth of population and export potential to neighbour countries like Kenya, Rwanda, Burundi, Congo, Sudan etc. Nonetheless the Government support by removal of taxes on imports of Pharmaceutical products, to sustain its policies of providing proper medication to people, also provided a vital support for its accelerating growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TITAN PHARMACEUTICALS TO EXPLORE STRATEGIC ALTERNATIVES

Titan Pharmaceuticals, Inc. | December 22, 2021

news image

Titan Pharmaceuticals, Inc. announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Co...

Read More

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

news image

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

PHASE 1 CLINICAL TRIAL FOR CORONAVIRUS VACCINE BEGINS IN SEATTLE

PharmaNewsIntelligence | March 17, 2020

news image

Phase 1 clinical trials for a coronavirus vaccine have begun at Kaiser Permanente Washington Health Research Institute (KPWHR) has begun, according to a statement from the National Institutes of Health. The investigational vaccination, funded in part by the National Institute of Allergy and Infectious Disease, began today by administering the first immunization to a healthy adult between ages 18 and 55 years old. In total, the phase 1 clinical trial will enroll 45 adults who fit this criteria an...

Read More

Pharma Tech

PFIZER, BIONTECH COVID-19 VACCINE WORKS IN MORE CONTAGIOUS CORONAVIRUS VARIANTS

Pfizer | January 11, 2021

news image

Newly emerged variants of the novel coronavirus have sparked a key question: Will existing COVID-19 vaccines be less effective against them? But scientists have preliminary data showing that may not be the case, at least for Pfizer and BioNTech’s shot. Researchers from the University of Texas and Pfizer found that, in lab dishes, the vaccine was able to neutralize an engineered version of a variant, which bears an N501Y mutation in its spike protein. The finding was publishe...

Read More
news image

Pharmacy Market

TITAN PHARMACEUTICALS TO EXPLORE STRATEGIC ALTERNATIVES

Titan Pharmaceuticals, Inc. | December 22, 2021

Titan Pharmaceuticals, Inc. announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Co...

Read More
news image

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

news image

PHASE 1 CLINICAL TRIAL FOR CORONAVIRUS VACCINE BEGINS IN SEATTLE

PharmaNewsIntelligence | March 17, 2020

Phase 1 clinical trials for a coronavirus vaccine have begun at Kaiser Permanente Washington Health Research Institute (KPWHR) has begun, according to a statement from the National Institutes of Health. The investigational vaccination, funded in part by the National Institute of Allergy and Infectious Disease, began today by administering the first immunization to a healthy adult between ages 18 and 55 years old. In total, the phase 1 clinical trial will enroll 45 adults who fit this criteria an...

Read More
news image

Pharma Tech

PFIZER, BIONTECH COVID-19 VACCINE WORKS IN MORE CONTAGIOUS CORONAVIRUS VARIANTS

Pfizer | January 11, 2021

Newly emerged variants of the novel coronavirus have sparked a key question: Will existing COVID-19 vaccines be less effective against them? But scientists have preliminary data showing that may not be the case, at least for Pfizer and BioNTech’s shot. Researchers from the University of Texas and Pfizer found that, in lab dishes, the vaccine was able to neutralize an engineered version of a variant, which bears an N501Y mutation in its spike protein. The finding was publishe...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us